Has Muhammad Shakir received payments from drug or device companies?

Yes. Drug and device makers reported $46,795 in general payments to Muhammad Shakir across 93 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Muhammad Shakir did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Muhammad Shakir come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Muhammad Shakir

Cardiovascular Disease · Newark, DENPI 1922529593

Payments from drug & device makers

What this record shows

This record is dominated by grants: $39,091 of the $46,795 with a category attached, or 83.5%. Medtronic accounts for 67.7% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2024 at $42,327 and has fallen 93.6% since, to $2,729 in 2025. Among cardiovascular disease clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$46,795in general payments, 2019–2025

Across 93 payments — averaging $503.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$32K
Abbott$13K
Edwards Lifesciences$563
Abiomed$405
Boston Scientific$306
AstraZeneca$254
plus $741 from 11 others

What the payments were for

Grants$39,09184%
Travel & lodging$3,4147%
Food & beverage$3,9498%
Education$3411%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic	20	$31,682
Abbott	30	$12,844
Edwards Lifesciences	4	$563
Abiomed	6	$405
Boston Scientific	2	$306
AstraZeneca	5	$254
E.r. Squibb & Sons, L.L.C.	9	$172
Pfizer	5	$125
Inari Medical, Inc.	1	$122
Cathworks, Inc.	1	$84
Novartis	4	$69
Penumbra, Inc.	1	$63
Novapproach Spine, LLC	1	$39
Kiniksa Pharmaceuticals International, PLC	1	$19
Bayer	1	$18
Kiniksa Pharmaceuticals, Ltd.	1	$17
AbbVie	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$46,795 in reported general payments places this provider in the 95th percentile of 104 cardiovascular disease providers in Delaware.

See all cardiovascular disease providers in Delaware →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Atorvastatin Calcium	17	$248
Amlodipine Besylate	11	$65

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Newark

Edward GoldenbergNewark$52K
Anthony AlfieriNewark$45K
Sean DikdanNewark$42K
Kirk GarrattNewark$38K
Anthony ClayNewark$37K
Ashish ParikhNewark$26K
William WeintraubNewark$24K
Wen Chi TsaiNewark$20K
Stephen MengNewark$17K
Francis PalermoNewark$17K

See the full list for Delaware →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →